Cerco Medical believes that success for the bio-artificial pancreas is near with the proper use of its patented proprietary technology. In the next few years it will emerge as an important new diabetes therapy. The crucial issue is proving how robust the solution is. We believe Cerco Medical will prove that our immune barrier is robust and the leading approach for encapsulation, allowing us to lead the industry and providing our investors with a superior return.